title: Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide.
abstract: Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.
authors.affiliation: Division of Hematology/Oncology, Cincinnati Children's Hospital, Cincinnati, Ohio 45249, USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Rayburg
authors.forename: Alexander
authors.initials: A
authors.lastname: Towbin
authors.forename: Hong
authors.initials: H
authors.lastname: Yin
authors.forename: Todd
authors.initials: T
authors.lastname: Maugans
authors.forename: Barry
authors.initials: B
authors.lastname: Maurer
authors.forename: Rajaram
authors.initials: R
authors.lastname: Nagarajan
authors.forename: Brian
authors.initials: B
authors.lastname: Weiss
mesh_terms: D001859:Bone Neoplasms / Q000209:etiology; D002648:Child; D017313:Fenretinide / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008297:Male; D009447:Neuroblastoma / Q000150:complications* / Q000188:drug therapy
chemical_list: D017313:Fenretinide